Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 12, Issue 4, 2009, Pages 333-338

  Freedland, S J ^a   Eastham, J ^b   Shore, N ^c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Carolina Urologic Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; DEGARELIX; DIETHYLSTILBESTROL; FLUTAMIDE; GOSERELIN; LEUPRORELIN; NILUTAMIDE; TRIPTORELIN;

AMNESIA; ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; BONE REMODELING; DRUG MECHANISM; ESTROGEN DEFICIENCY; FRAGILITY FRACTURE; GYNECOMASTIA; HOT FLUSH; HUMAN; LIPID BLOOD LEVEL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; ESTROGENS; FRACTURES, BONE; GONADOTROPIN-RELEASING HORMONE; GYNECOMASTIA; HOT FLASHES; HUMANS; LIPID METABOLISM; MALE; MEMORY DISORDERS; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RISK; TESTOSTERONE;

EID: 70649089017     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2009.35     Document Type: Review

References (49)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Pirtskhalaishvili G, Hrebinko RL, Nelson JB. The treatment of prostate cancer: An overview of current options. Cancer Pract 2001; 9 295-306.
3. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308.
4. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238-244.
5. Higano CS. Side effects of androgen deprivation therapy: Monitoring and minimizing toxicity. Urology 2003; 61 (2 Suppl 1): 32-38.
6. Chan JM, Jou RM, Carroll PR. The relative impact and future burden of prostate cancer in the United States. J Urol 2004; 172 (5 Part 2): S13-S16; discussion S17.
7. Flaig TW, Glode LM. Management of the side effects of androgen deprivation therapy in men with prostate cancer. Expert Opin Pharmacother 2008; 9: 2829-2841.
8. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002; 52: 154-179.
9. Smith MR, Malkowicz SB, Chu F, Forrest J, Price D, Sieber P et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: Interim analysis of a multicenter phase 3 clinical study. J Urol 2008; 179: 152-155.
10. Guise TA, Oefelein MG, Eastham JA, Cookson MS, Higano CS, Smith MR. Estrogenic side effects of androgen deprivation therapy. Rev Urol 2007; 9: 163-180.
11. Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 1996; 11: 150-159.
12. Manolagas SC. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21: 115-137.
13. Manolagas SC, Weinstein RS, Bellido T, Bodenner DL. Opposite effects of estrogen on the life span of osteoblasts/osteocytes vs. osteoclasts in vivo and in vitro: An explanation of the imbalance between formation and resportion in estrogen deficiency. J Bone Miner Res 1999; 14: S169.
14. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724-731.
15. Hannan MT, Felson DT, Anderson JJ. Bone mineral density in elderly men and women: Results from the Framingham osteoporosis study. J Bone Miner Res 1992; 7: 547-553.
16. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-164.
17. Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K. Fracture risk in Danish men with prostate cancer: A nationwide register study. BJU Int 2007; 100: 749-754.
18. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897-7903.
19. Lee H, McGovern K, Finkelstein JS, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 2005; 104: 16331637.
20. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 6410-6417.
21. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168: 1005-1007.
22. Yee EF, White RE, Murata GH, Handanos C, Hoffman RM. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med 2007; 22: 1305-1310.
23. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002; 77: 1207-1218.
24. Karling P, Hammar M, Varenhorst E. Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol 1994; 152: 1170-1173.
25. Schow DA, Renfer LG, Rozanski TA, Thompson IM. Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 1998; 91: 855-857.
26. Nishiyama T, Kanazawa S,Watanabe R, Terunuma M, Takahashi K. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol 2004; 11 735-741.
27. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A et al. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 1993; 11 (3): 570-579.
28. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997; 50: 920-928.
29. Ulloa EW, Salup R, Patterson SG, Jacobsen PB. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer. Psychooncology 2008; 18: 598-605.
30. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: A measure of subjective stress. Psychosom Med 1979; 41: 209-218.
31. Chen AC, Petrylak DP. Complications of androgen-deprivation therapy in men with prostate cancer. Curr Urol Rep 2005; 6: 210-216.
32. Autorino R, Perdonà S, D'Armiento M, De Sio M, Damiano R, Cosentino L et al. Gynecomastia in patients with prostate cancer: Update on treatment options. Prostate Cancer Prostatic Dis 2006; 9: 109-114.
33. Wassersug RJ, Oliffe JL. The social context for psychological distress from iatrogenic gynecomastia with suggestions for its management. J Sex Med 2008; 6: 989-1000.
34. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 44484456.
35. Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: Differences from the classic metabolic syndrome. Cancer 2008; 112: 2188-2194.
36. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 1801-1811.
37. Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 2006; 18: 494-498.
38. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87 599-603.
39. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009; 27: 92-99.
40. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
41. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24 3979-3983.
42. Beer TM, Bland LB, Bussiere JR, Neiss MB, Wersinger EM, Garzotto M et al. Testosterone loss and estradiol administration modify memory in men. J Urol 2006; 175: 130-135.
43. Salminen EK, Portin RI, Koskinen AI, Helenius HY, Nurmi MJ. Estradiol and cognition during androgen deprivation in men with prostate carcinoma. Cancer 2005; 103: 1381-1387.
44. Cherrier MM, Matsumoto AM, Amory JK, Ahmed S, Bremner W, Peskind ER et al. The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology 2005; 64: 290-296.
45. Salminen EK, Portin RI, Koskinen A, Helenius H, Nurmi M. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res 2004; 10: 7575-7582.
46. Eastham JA. Bone health in men receiving androgen deprivation therapy for prostate cancer. J Urol 2007; 177: 17-24.
47. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 2004; 61: 332-353.
48. Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th edn. McGraw-Hill Companies Inc., 2006.
49. Gao W, Dalton JT. Ockham's razor and selective androgen receptor modulators (SARMs): Are we overlooking the role of 5alpha-reductase? Mol Interv 2007; 7: 10-13.